|
Fig. 6
Figure 6. AZ Dyrk1B 33 increases the prevalence of incretin+ cells and improves glucose control in diabetic mice (A and B) AZ Dyrk1B 33 improves the normalization of glucose during OGTT in diabetic mice. (A) Pooled data from two OGTT experiments in BKS db/db mice treated by AZ Dyrk1B 33 or vehicle. The mice were fasted before the administration of glucose (0.5 mg/kg). (B) The area under the curve for the OGTT in (A) (0–120 min). ∗∗p < 0.005, ∗p < 0.05. n = 10 AZ Dyrk1B 33-treated mice; and n = 9 vehicle-treated mice. (C) The serum GIP level increases in AZ Dyrk1B 33-treated diabetic mice after a glucose challenge. Blood samples were collected before and at 15 min after the administration of glucose (0.5 mg/kg). GIP levels were normalized to the corresponding GIP levels in the sera sampled in the fasted state before the administration of glucose. ∗p < 0.05. (D–G) AZ Dyrk1B 33 increases the number of incretin+ cells in diabetic mice. (D and E) Representative confocal images of the small intestines of mice treated with vehicle or AZ Dyrk1B 33, displaying K-cells in green, L-cells in red, and DAPI in blue. Scale bars, 100 μm. (F and G) Quantification of the number of GIP-expressing K-cells (F) and GLP-1-expressing L-cells (G). The total numbers of cells were normalized to the DAPI area (per mm2). n = 4 mice per group. ∗∗p < 0.001. (H–J) AZ Dyrk1B 33 does not change the amount of α- or β-cells in diabetic mouse pancreata. (H and I) Representative confocal images of the pancreata of BKS db/db mice treated with vehicle (H) or AZ Dyrk1B 33 (I), displaying β-cells in green, α-cells in red, and DAPI in blue. Scale bars, 100 μm. (J) Quantification of α- and β-cell mass. n = 4 mice per group. See also Figure S4.